{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:17:38Z","timestamp":1782836258759,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"MEMORIAL SLOAN KETTERING CANCER CENTER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtct.2025.09.015","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:36:44Z","timestamp":1757342204000},"page":"1004.e1-1004.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed\/Refractory Large B-cell Lymphoma"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markqayne D.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael A.","family":"Rodriguez-Guadarrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Blissett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.09.015_bib0001","series-title":"Yescarta (axicabtagene ciloleucel) Prescribing information","year":"2021"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.015_bib0004","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.015_bib0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-Cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2025.09.015_bib0006","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1182\/blood-2023-181255","article-title":"statistical challenges from trials of potentially curative treatments: validation of cure assumptions when analyzing zuma-7 follow-up data of axi-cel and standard of care therapy","volume":"142","author":"Patel","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.015_bib0007","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jval.2021.10.015","article-title":"Predicting survival for chimeric antigen receptor t-cell therapy: a validation of survival models using follow-up data from ZUMA-1","volume":"25","author":"Vadgama","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jtct.2025.09.015_bib0008","unstructured":"Guide to the methods of technology appraisal 2013 (2013)."},{"key":"10.1016\/j.jtct.2025.09.015_bib0009","unstructured":"NISE DSU Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials - Extrapolation with patient-level data (2013)."},{"key":"10.1016\/j.jtct.2025.09.015_bib0010","unstructured":"NICE DSU Technical Support Document 21: Flexible methods for survival analysis (2020)."},{"issue":"10","key":"10.1016\/j.jtct.2025.09.015_bib0011","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40273-024-01406-7","article-title":"Mixture and non-mixture cure models for health technology assessment: what you need to know","volume":"42","author":"Latimer","year":"2024","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.015_bib0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s41669-021-00260-z","article-title":"Mixture cure models in oncology: a tutorial and practical guidance","volume":"5","author":"Felizzi","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.015_bib0013","doi-asserted-by":"crossref","first-page":"750.e1","DOI":"10.1016\/j.jtct.2022.08.010","article-title":"The cost-effectiveness of Axicabtagene Ciloleucel as second-line therapy in patients with large B-Cell lymphoma in the United States: an economic evaluation of the ZUMA-7 trial","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.015_bib0014","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/13696998.2023.2290832","article-title":"An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States","volume":"27","author":"Oluwole","year":"2024","journal-title":"J Med Econ"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45956","article-title":"Cost-effectiveness of Axicabtagene Ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"5","author":"Choe","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.015_bib0016","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/bloodadvances.2023011793","article-title":"Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma","volume":"8","author":"Choe","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.jtct.2025.09.015_bib0017","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2022016747","article-title":"Cost-effectiveness of second-line Axicabtagene Ciloleucel in relapsed refractory diffuse large B-cell lymphoma","volume":"140","author":"Kambhampati","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.015_bib0018","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1200\/JCO.22.00478","volume":"41","author":"Vijenthira","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.015_bib0019","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.7326\/M22-2276","article-title":"Second-line chimeric antigen receptor t-cell therapy in diffuse large B-cell lymphoma : a cost-effectiveness analysis","volume":"176","author":"Kelkar","year":"2023","journal-title":"Ann Intern Med"},{"issue":"14","key":"10.1016\/j.jtct.2025.09.015_bib0020","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.015_bib0021","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jtct.2025.09.015_bib0022","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.jtct.2025.09.015_bib0023","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2025.09.015_bib0024","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.015_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40273-019-00867-5","article-title":"A case study examining the usefulness of cure modelling for the prediction of survival based on data maturity","volume":"38","author":"Grant","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.015_bib0026","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jval.2021.05.009","article-title":"The extrapolation performance of survival models for data with a cure fraction: a simulation study","volume":"24","author":"Kearns","year":"2021","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jtct.2025.09.015_bib0027","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jval.2018.10.007","article-title":"Survival extrapolation in cancer immunotherapy: a validation-based case study","volume":"22","author":"Bullement","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jtct.2025.09.015_bib0028","doi-asserted-by":"crossref","unstructured":"Kasle A., Qu T, Meng Y. Review and comparison of overall survival extrapolation in health technology assessments CAR-T therapies. 2020","DOI":"10.1016\/j.jval.2020.04.100"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.015_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2021-000094","article-title":"Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness","volume":"1","author":"Latimer","year":"2022","journal-title":"BMJ Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.015_bib0030","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","article-title":"Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations","volume":"37","author":"Ouwens","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.015_bib0031","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtct.2022.06.019","article-title":"Role of CD19 chimeric antigen receptor t cells in second-line large b cell lymphoma: lessons from phase 3 trials. an expert panel opinion from the American society for transplantation and cellular therapy","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"19","key":"10.1016\/j.jtct.2025.09.015_bib0032","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.015_bib0033","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jtct.2025.09.015_bib0034","unstructured":"Kite AGC. Data on file. ZUMA-7 subsequent therapy at 4-year follow-up. 2025."},{"issue":"1","key":"10.1016\/j.jtct.2025.09.015_bib0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.015_bib0036","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1007\/s12325-021-01841-4","article-title":"Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: evidence from a systematic literature review","volume":"38","author":"Sussman","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtct.2025.09.015_bib0037","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.bbmt.2017.12.318","article-title":"Estimating long-term survival for patients with relapsed or refractory aggressive Non-Hodgkin lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy: a comparison of standard and mixture cure models","volume":"24","author":"Bansal","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.015_bib0038","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/0272989X16639900","article-title":"Extrapolating survival from randomized trials using external data: a review of methods","volume":"37","author":"Jackson","year":"2017","journal-title":"Med Decis Making"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T01:13:33Z","timestamp":1772932413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666636725014393"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed\/Refractory Large B-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}